Currently, the treatment regimen timeline for patients with (M.tb) can extend over 6 months with combination drug therapy. The extended timeframe of treatment has a poor success rate and can give rise to the development of multi-drug resistance (M.tb) strains. One roadblock in the development of more effective and efficient drugs is the lack of appropriate model systems to mimic the human model that develops the mature granuloma structures. This structure serves to limit the spread of infection but acts as a biological barrier to effective drug therapy. In this $250,000 grant from ACTG entitled “A Mouse Model to Determine the In Vivo Efficacy of Anti-Mycobacterial Drugs against M. Tuberculosis,” Dr. Joanne Turner will investigate the potential of CBA/J IL-10 KO mouse developed in her laboratory as a new model for the rapid screening of the efficacy of current and new anti-mycobacterial drugs in penetrating mature granulomas. These findings will show proof-of-principle that the CBA/J IL-10 KO mouse model can be used in drug screening to identify new treatments that will be able to penetrate the granuloma, identifying drugs that are likely to significantly shorten treatment time for (M.tb) infection.